Analysts Offer Insights on Healthcare Companies: Ocular Therapeutix (OCUL), Adaptimmune Therapeutics (ADAP) and Arcutis Biotherapeutics (ARQT)
Analysts Offer Insights on Healthcare Companies: Adaptimmune Therapeutics (ADAP), Elevation Oncology (ELEV) and AC Immune SA (ACIU)
New Share Price & Shareholder Rights Risk for Adaptimmune Therapeutics Plc. – What's the Latest?
Adaptimmune Therapeutics (ADAP) Receives a Sell From Barclays
Analysts' Opinions Are Mixed on These Healthcare Stocks: Insulet (PODD) and Adaptimmune Therapeutics (ADAP)
Analysts Are Bullish on These Healthcare Stocks: Adaptimmune Therapeutics (ADAP), CymaBay Therapeutics (CBAY)
Buy Rating for Adaptimmune Therapeutics Amidst FDA Priority Review and Significant Upside Potential
Analysts Conflicted on These Healthcare Names: Adaptimmune Therapeutics (ADAP) and Tandem Diabetes Care (TNDM)
Analysts Offer Insights on Healthcare Companies: Nkarta (NKTX), Adaptimmune Therapeutics (ADAP) and Corvus Pharmaceuticals (CRVS)
Analysts Have Conflicting Sentiments on These Healthcare Companies: ADMA Biologics (ADMA), Adaptimmune Therapeutics (ADAP) and Bioxcel Therapeutics (BTAI)
JonesTrading Sticks to Their Hold Rating for Adaptimmune Therapeutics (ADAP)
Analysts Offer Insights on Healthcare Companies: Adaptimmune Therapeutics (ADAP), Crinetics Pharmaceuticals (CRNX) and PolyPid (PYPD)
Promising Clinical Results and Growth Opportunities: A Buy Rating for Adaptimmune Therapeutics
Promising Clinical Data and Potential Commercial Transition Bolster Buy Rating for Adaptimmune Therapeutics: An Analyst's Perspective
Hold Rating on Adaptimmune Therapeutics Amid Phase I SURPASS Trial Results: Insights on Efficacy, Safety Concerns, and Future Expectations
Hold Rating on Adaptimmune Therapeutics: Promising Updates but Significant Uncertainties Persist
Positive Trial Results and Future Growth Prospects Drive Buy Rating for Adaptimmune Therapeutics
EF Hutton Reiterates Buy on Adaptimmune Therapeutics, Maintains $10 Price Target
Adaptimmune Therapeutics (ADAP) Receives a New Rating From Barclays
Adaptimmune Therapeutics (ADAP) Gets a Buy From Mizuho Securities
No Data